CN103687594A - 眼科治疗 - Google Patents

眼科治疗 Download PDF

Info

Publication number
CN103687594A
CN103687594A CN201280025096.6A CN201280025096A CN103687594A CN 103687594 A CN103687594 A CN 103687594A CN 201280025096 A CN201280025096 A CN 201280025096A CN 103687594 A CN103687594 A CN 103687594A
Authority
CN
China
Prior art keywords
eye
compositions
composition
opioid
tramadol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280025096.6A
Other languages
English (en)
Chinese (zh)
Inventor
安纳特·夏尔马
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
O F Toso J Research & Development Ltd
Original Assignee
Optosolve Research and Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1105732.0A external-priority patent/GB201105732D0/en
Priority claimed from GBGB1105731.2A external-priority patent/GB201105731D0/en
Application filed by Optosolve Research and Development Ltd filed Critical Optosolve Research and Development Ltd
Priority to CN201711200533.4A priority Critical patent/CN107982211A/zh
Publication of CN103687594A publication Critical patent/CN103687594A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201280025096.6A 2011-04-05 2012-04-05 眼科治疗 Pending CN103687594A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711200533.4A CN107982211A (zh) 2011-04-05 2012-04-05 眼科治疗

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1105731.2 2011-04-05
GBGB1105732.0A GB201105732D0 (en) 2011-04-05 2011-04-05 Ophthalmic lubricants
GB1105732.0 2011-04-05
GBGB1105731.2A GB201105731D0 (en) 2011-04-05 2011-04-05 Topical analgesics
PCT/GB2012/000330 WO2012136969A2 (en) 2011-04-05 2012-04-05 Ophthalmic treatments

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201711200533.4A Division CN107982211A (zh) 2011-04-05 2012-04-05 眼科治疗

Publications (1)

Publication Number Publication Date
CN103687594A true CN103687594A (zh) 2014-03-26

Family

ID=46086008

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280025096.6A Pending CN103687594A (zh) 2011-04-05 2012-04-05 眼科治疗
CN201711200533.4A Pending CN107982211A (zh) 2011-04-05 2012-04-05 眼科治疗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201711200533.4A Pending CN107982211A (zh) 2011-04-05 2012-04-05 眼科治疗

Country Status (12)

Country Link
US (2) US20140088199A1 (enExample)
EP (2) EP2694048B1 (enExample)
JP (2) JP6148664B2 (enExample)
KR (2) KR102165246B1 (enExample)
CN (2) CN103687594A (enExample)
BR (1) BR112013025493A2 (enExample)
CA (1) CA2869280C (enExample)
ES (1) ES2836808T3 (enExample)
HK (1) HK1254720A1 (enExample)
MA (1) MA35070B1 (enExample)
MX (1) MX346312B (enExample)
WO (1) WO2012136969A2 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105232449A (zh) * 2015-10-30 2016-01-13 上海昊海生物科技股份有限公司 盐酸莫西沙星透明质酸钠缓释纳米凝胶及其制备方法
CN110996954A (zh) * 2017-06-08 2020-04-10 眼科治疗有限责任公司 低剂量的溴莫尼定组合及其用途
CN111655241A (zh) * 2017-12-15 2020-09-11 塔苏斯制药有限公司 用于治疗睑炎的异恶唑啉驱虫剂制剂和方法
CN112007028A (zh) * 2020-09-03 2020-12-01 北京博纳致恒科技有限责任公司 一种复合睫状肌松弛剂的人工泪液及用途
CN113577097A (zh) * 2015-09-24 2021-11-02 基质生物研究所 高弹性透明质酸组合物及其使用方法
US12257263B2 (en) 2014-08-04 2025-03-25 Tarsus Pharmaceuticals, Inc. Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
US12502377B2 (en) 2025-06-18 2025-12-23 Tarsus Pharmaceuticals, Inc. Method of eradicating ticks that attach to humans using lotilaner formulations

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX346312B (es) * 2011-04-05 2017-03-15 Optosolve Res & Dev Ltd Tratamientos oftalmicos.
GB201217522D0 (en) * 2012-10-01 2012-11-14 Sharma Anant ophthalmic therapy
WO2014167327A1 (en) * 2013-04-09 2014-10-16 Cresset Biomolecular Discovery Ltd The treatment of inflammatory disorders
ES2540151B1 (es) * 2013-10-11 2016-02-29 Farmalider S.A. Composición farmacéutica de ibuprofeno y tramadol para uso oftálmico
RU2549472C1 (ru) * 2013-12-26 2015-04-27 Илья Александрович Марков Фармацевтическая композиция в форме капель для профилактики и лечения аллергических заболеваний глаз
JP2017502089A (ja) * 2014-01-10 2017-01-19 マニスティー パートナーズ エルエルシーＭａｎｉｓｔｅｅ Ｐａｒｔｎｅｒｓ Ｌｌｃ 偏頭痛の処置
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US9877964B2 (en) 2015-02-24 2018-01-30 Ocugen, Inc. Methods and compositions for treating dry eye disease and other eye disorders
AU2016222902A1 (en) * 2015-02-24 2017-08-31 Ocugen, Inc. Methods and compositions for treating dry eye disease and other eye disorders
US11052094B2 (en) 2015-05-29 2021-07-06 Sydnexis, Inc. D2O stabilized pharmaceutical formulations
ES2604816B1 (es) 2015-09-09 2018-01-29 Farmalider, S.A. Composición farmacéutica de tramadol para uso oftálmico
WO2017059088A1 (en) * 2015-09-30 2017-04-06 George Edward Hoag Topical analgesic pain relife formulations, manufacture and methods of use thereof
EP4241759A1 (en) * 2016-10-12 2023-09-13 PS Therapy, Inc. Artificial tear, contact lens and drug vehicle compositions and methods of use thereof
WO2018212846A1 (en) 2017-05-19 2018-11-22 Ocugen, Inc. Ophthalmic compositions and methods of use
MX2018003456A (es) 2017-12-21 2019-09-06 Gruenenthal Gmbh Combinacion farmaceutica en la forma de comprimidos en bicapa que comprende ketorolaco trometamina y tramadol clorhidrato, y su uso para el tratamiento del dolor.
CN111886001A (zh) * 2018-03-13 2020-11-03 参天制药株式会社 滴眼型洗眼药用组合物
FR3096890B1 (fr) * 2019-06-07 2021-05-14 H4 Orphan Pharma Utilisation d’une molécule opioïde pour traiter l’œil sec et l’œil allergique.
US20220265695A1 (en) 2019-07-26 2022-08-25 Proqr Therapeutics Ii B.V. Opthalmic compositions comprising viscosifying polymers and nucleic acids
US11504269B2 (en) 2019-11-19 2022-11-22 Jennifer L. Fabian Therapeutic bra
WO2021163304A1 (en) * 2020-02-11 2021-08-19 Tufts Medical Center, Inc. Activation of neuropeptide receptors on plasmacytoid dendritic cells to treat or prevent ocular diseases associated with neovascularization and inflammation
EP4297741A4 (en) * 2021-02-26 2025-02-26 Vyluma Inc. METHODS AND FORMULATIONS FOR TOPICAL ADMINISTRATION OF GABAPENTINOIDS
WO2023285878A1 (en) * 2021-07-13 2023-01-19 Aviation-Ophthalmology Methods for detecting, treating, and preventing gpr68-mediated ocular diseases, disorders, and conditions
EP4534081A1 (en) * 2022-07-06 2025-04-09 Rohto Pharmaceutical Co., Ltd. Ophthalmic composition
TW202408474A (zh) * 2022-07-06 2024-03-01 學校法人金澤醫科大學 疼痛抑制劑
TW202408468A (zh) * 2022-07-06 2024-03-01 日商樂敦製藥股份有限公司 眼科組成物
JPWO2024010040A1 (enExample) * 2022-07-06 2024-01-11
WO2025146828A1 (ja) * 2024-01-05 2025-07-10 ロート製薬株式会社 眼科組成物
WO2025159099A1 (ja) * 2024-01-24 2025-07-31 国立大学法人北海道大学 医薬組成物、眼瞼けいれん処置薬、知覚過敏またはジストニア処置薬、および症状モデルマウス

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6384043B1 (en) 1993-02-01 2002-05-07 Gholam A. Peyman Methods of alleviating pain sensations of the denuded eye with opioid analgesics
US6017963A (en) * 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
ATE214272T1 (de) * 1996-12-16 2002-03-15 Alcon Lab Inc Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
JP2004143157A (ja) * 2002-10-01 2004-05-20 Taisho Pharmaceut Co Ltd 点眼剤
US20060172972A1 (en) * 2002-12-20 2006-08-03 Chakshu Research Inc Formulation and method for administration of ophthalmologically active agents
SG173326A1 (en) 2004-06-04 2011-08-29 Camurus Ab Liquid depot formulations
EP1611877A1 (en) * 2004-06-28 2006-01-04 Universidade de Coimbra Method for preparing sustained-release therapeutic ophthalmic articles using compressed fluids for impregnation of drugs
WO2007057508A2 (en) 2005-11-18 2007-05-24 Orion Corporation Treatment of pain with a combination of an alpha2 -adrenoceptor antagonist such as atipemezole or fipamezoiie and an opioid receptor agonist, such as tramadol
US20090010850A1 (en) 2007-05-24 2009-01-08 Ousler Iii George W Formulations and methods for treating dry eye
CA2636646A1 (en) * 2006-01-25 2007-08-02 Aciex, Inc. Formulations and methods for treating dry eye
EP2311446A1 (en) * 2009-10-16 2011-04-20 Laboratorios Del. Dr. Esteve, S.A. Compositions comprising Tramadol and Celecoxib in the treatment of pain
MX346312B (es) * 2011-04-05 2017-03-15 Optosolve Res & Dev Ltd Tratamientos oftalmicos.

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
ALCON LABORATORIES: "Tears Naturale II", 《TEARS NATURALE II POLYQUAD》 *
BAUDOUIN ET AL: "Current treatment of xerophthalmia in Sjogren"s syndrome", 《REVUE DE MEDECINE INTERNE》 *
FAKTOROVICH ET AL: "Effect of topical 0.5% morphine on postoperative pain after photorefractive keratectomy", 《J.REFRACT.SURG.》 *
GARLICKI JAROSLOW ET AL: "Effects of intraarticular tramadol administration in the rat model of knee joint inflammation", 《PHARMACOLOGICAL REPORTS》 *
KO BYOUNG-WOO ET AL: "Analgesic effects of tramadol during panretinal photocoagulation", 《KOREAN JOURNAL OF OPHTHALMOLOGY》 *
PARHIZKARI G ET AL: "A stability-indicating HPLC method for the determination of benzalkonium chloride in 0.5% Tramadol ophthalmic solution", 《CHROMATOGRAPHIA》 *
PEYMAN G A K ET AL: "Effects of morphine on corneal sensitivity and epithelial wound healing:implications for topical ophthalmic analgesia", 《BRITISH JOURNAL OF OPHTHALMOLOGY》 *
STILES JEAN ET AL: "Effect of topical administration of 1% morphine sulfate solution on signs of pain and corneal wound healing in dogs", 《AMERICAN JOURNAL OF VETERINARY RESEARCH》 *
T.F.LIN ET AL: "Compatibility and Stability of Binary Mixtures of Ketorolac Tromethamine and Tramadol Hydrochloride Injection Concentrate and Diluted Infusion Solution", 《ACTA ANAESTHESIOL.TAIWAN》 *
TARANTINI A ET AL: "Peribulbar tramadol,clonidine,and ropivacaine in blind and seeing painful eyes", 《EUROPEAN JOURNAL OF OPHTHALMOLOGY》 *
ZOLLNER CHRISTIAN ET AL: "Topical fentanyl in randomized,double-blind study in patients with corneal damage", 《THE CLINICAL JOURNAL OF PAIN》 *
李战等: "曲马多控制准分子激光上皮下角膜磨削术后疼痛的临床观察", 《眼科学报》 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12257263B2 (en) 2014-08-04 2025-03-25 Tarsus Pharmaceuticals, Inc. Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
CN113577097A (zh) * 2015-09-24 2021-11-02 基质生物研究所 高弹性透明质酸组合物及其使用方法
CN105232449A (zh) * 2015-10-30 2016-01-13 上海昊海生物科技股份有限公司 盐酸莫西沙星透明质酸钠缓释纳米凝胶及其制备方法
CN105232449B (zh) * 2015-10-30 2019-04-09 上海昊海生物科技股份有限公司 盐酸莫西沙星透明质酸钠缓释纳米凝胶及其制备方法
CN110996954A (zh) * 2017-06-08 2020-04-10 眼科治疗有限责任公司 低剂量的溴莫尼定组合及其用途
CN111655241A (zh) * 2017-12-15 2020-09-11 塔苏斯制药有限公司 用于治疗睑炎的异恶唑啉驱虫剂制剂和方法
US12213964B2 (en) 2017-12-15 2025-02-04 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations
US12364685B2 (en) 2017-12-15 2025-07-22 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations
CN112007028A (zh) * 2020-09-03 2020-12-01 北京博纳致恒科技有限责任公司 一种复合睫状肌松弛剂的人工泪液及用途
US12502377B2 (en) 2025-06-18 2025-12-23 Tarsus Pharmaceuticals, Inc. Method of eradicating ticks that attach to humans using lotilaner formulations

Also Published As

Publication number Publication date
KR20190004815A (ko) 2019-01-14
US9913813B2 (en) 2018-03-13
JP2017141243A (ja) 2017-08-17
US20140088199A1 (en) 2014-03-27
US20160199320A1 (en) 2016-07-14
CA2869280C (en) 2020-03-10
JP2014513073A (ja) 2014-05-29
ES2836808T3 (es) 2021-06-28
HK1254720A1 (zh) 2019-07-26
CN107982211A (zh) 2018-05-04
CA2869280A1 (en) 2012-10-11
KR102165246B1 (ko) 2020-10-13
BR112013025493A2 (pt) 2017-03-01
WO2012136969A3 (en) 2013-01-03
JP6419876B2 (ja) 2018-11-07
WO2012136969A2 (en) 2012-10-11
MX2013011314A (es) 2014-03-27
MX346312B (es) 2017-03-15
EP3799866A1 (en) 2021-04-07
EP2694048B1 (en) 2020-10-07
KR20140145948A (ko) 2014-12-24
MA35070B1 (fr) 2014-04-03
EP2694048A2 (en) 2014-02-12
JP6148664B2 (ja) 2017-06-14

Similar Documents

Publication Publication Date Title
US9913813B2 (en) Opthalmic treatments
ES2376172T5 (es) Compuestos, formulaciones y métodos para tratar o prevenir la rosácea
CN1684701B (zh) 眼科冲洗液及方法
ES2759781T3 (es) Composiciones y tratamiento para enfermedades y trastornos oculares
US8530449B2 (en) Composition for a topical ophthalmic clear colloidal liquid which undergoes a liquid-gel phase transition in the eye
JP2014513073A5 (enExample)
JP2003522785A (ja) 眼痛の処置方法
CA2780453A1 (en) Treating xerophthalmia with compounds increasing meibomian gland secretion
WO2012073077A1 (en) Folic acid - ramipril combination: cellprotective, neuroprotective and retinoprotective ophtalmologic compositions
JP2001521500A (ja) 緑内障に関連する視神経変性を防止する薬剤の製造におけるナトリウムチャンネル遮断剤の使用
US9187468B2 (en) Topical ocular analgesic agents
CN103202833A (zh) 一种奥洛他定或其盐的药用组合物及其制备方法
Alany et al. Novel ocular drug delivery systems in glaucoma
RU2772357C2 (ru) Состав для эффективной доставки липидов в слезную пленку человека с использованием чувствительной к соли эмульсионной системы
US20230064711A1 (en) Compositions, kits and methods for enhancing therapeutic compliance
JP2021517139A (ja) 選択的ｓｙｋ阻害剤の使用方法および医薬組成物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: OPTOSOLVE RESEARCH + DEVELOPMENT LTD.

Free format text: FORMER OWNER: OPTOSOLVE LLP

Effective date: 20150318

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20150318

Address after: British Bermingham

Applicant after: O F Toso J Research & Development Ltd

Address before: British Bermingham

Applicant before: OPTOSOLVE LLP

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20140326